The triptans

被引：9

作者：

Bigal, Marcelo E. ^{[1
,2
]}

Krymchantowski, Abouch V. ^{[3
,4
]}

Hargreaves, Richard ^{[5
]}

机构：

[1] Merck Res Labs, Global Director Sci Affairs, Whitehouse Stn, NJ 08889 USA

[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA

[3] Univ Fed Fluminense, Headache Ctr Rio, Rio De Janeiro, Brazil

[4] Univ Fed Fluminense, Dept Neurol, Rio De Janeiro, Brazil

[5] Merck Res Labs, Basic Res, Whitehouse Stn, NJ USA

来源：

EXPERT REVIEW OF NEUROTHERAPEUTICS | 2009年 / 9卷 / 05期

关键词：

5-hydroxytryptamine; migraine; triptan; GENE-RELATED PEPTIDE; ORALLY DISINTEGRATING TABLET; DECREASES MIGRAINE RECURRENCE; SEROTONIN 5-HT1B/1D AGONISTS; ZOLMITRIPTAN NASAL SPRAY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ANTIMIGRAINE DRUG; TRIGEMINOVASCULAR SYSTEM; SUBCUTANEOUS SUMATRIPTAN;

D O I：

10.1586/ERN.09.15

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The migraine-specific triptans have revolutionized the treatment of migraine and are currently the drugs of choice to treat a migraine attack in progress. Over the past 15 years, triptans were released in rapid succession, with each one demonstrating some specific pharmacokinetic properties that may be translated into clinical advantages. Triptans share many similarities, but also have important differences from one another. Accordingly, herein we discuss the class of the triptans. We first define the trigeminovascular system and its importance in migraine pain, then discuss the mechanism of action of the triptans and contrast the evidence supporting the use of different triptans. We close with our view of the future and hopes for the next generation of antimigraine therapies.

引用

页码：649 / 659

页数：11

共 107 条

[1] Efficacy and safety of rizatriptan wafer for the acute treatment of migraine [J].

Ahrens, SP ;

Farmer, MV ;

Williams, DL ;

Willoughby, E ;

Jiang, K ;

Block, GA ;

Visser, WH .

CEPHALALGIA, 1999, 19 (05) :525-530

[2] L-694,247 - A POTENT 5-HT(1D) RECEPTOR AGONIST [J].

BEER, MS ;

STANTON, JA ;

BEVAN, Y ;

HEALD, A ;

REEVE, AJ ;

STREET, LJ ;

MATASSA, VG ;

HARGREAVES, RJ ;

MIDDLEMISS, DN .

BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (03) :1196-1200

[3] Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine [J].

Bomhof, M ;

Paz, J ;

Legg, N ;

Allen, C ;

Vandormael, K ;

Patel, K .

EUROPEAN NEUROLOGY, 1999, 42 (03) :173-179

[4]

Bou J, 2001, CEPHALALGIA, V21, P804, DOI 10.1046/j.1468-2982.2001.00233.x

[5]

Boureau F, 2000, INT J CLIN PRACT, V54, P281

[6] Vascular actions of calcitonin gene-related peptide and adrenomedullin [J].

Brain, SD ;

Grant, AD .

PHYSIOLOGICAL REVIEWS, 2004, 84 (03) :903-934

[7] Sumatriptan-naproxen for acute treatment of migraine - A randomized trial [J].

Brandes, Jan Lewis ;

Kudrow, David ;

Stark, Stuart R. ;

O'Carroll, C. Phillip ;

Adelman, James U. ;

O'Donnell, Francis J. ;

Alexander, W. James ;

Spruill, Susan E. ;

Barrett, Pamela S. ;

Lener, Shelly E. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (13) :1443-1454

[8] Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing [J].

Brandes, JL ;

Kudrow, D ;

Cady, R ;

Tiseo, PJ ;

Sun, W ;

Sikes, CR .

CEPHALALGIA, 2005, 25 (09) :735-742

[9]

Burstein R, 2005, REV NEUROL-FRANCE, V161, P658

[10] Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization [J].

Burstein, R ;

Jakubowski, M .

ANNALS OF NEUROLOGY, 2004, 55 (01) :27-36

← 1 2 3 4 5 6 7 8 9 10 →